Michael McGarrity, CEO, discusses a balanced strategy of internal and acquisition-driven development. Revenue growth is fueled by urology and pathology adoption, with focus on tissue-based tests. Market access efforts aim to optimize payer mix distribution. Early uptake of germline test shows promise for future revenue.